Trastuzumab deruxtecan + 5FU/LV + Trastuzumab deruxtecan + FLO
Phase 1/2Recruiting 0 watching 0 views this week⚡ Active
41
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Esophagogastric Adenocarcinoma
Conditions
Esophagogastric Adenocarcinoma
Trial Timeline
Mar 25, 2025 → Dec 31, 2027
NCT ID
NCT06731803About Trastuzumab deruxtecan + 5FU/LV + Trastuzumab deruxtecan + FLO
Trastuzumab deruxtecan + 5FU/LV + Trastuzumab deruxtecan + FLO is a phase 1/2 stage product being developed by Daiichi Sankyo for Esophagogastric Adenocarcinoma. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06731803. Target conditions include Esophagogastric Adenocarcinoma.
Hype Score Breakdown
Clinical
13
Activity
8
Company
10
Novelty
4
Community
3
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06731803 | Phase 1/2 | Recruiting |
Competing Products
6 competing products in Esophagogastric Adenocarcinoma
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Pembrolizumab + Trastuzumab + FLOT | Merck | Phase 2 | 52 |
| bevacizumab + capecitabine + cisplatin + Epirubicin + Lapatinib | Roche | Phase 2/3 | 65 |
| Capecitabine + Epirubicin + AMG 102 + Cisplatin + Placebo | Amgen | Phase 1/2 | 40 |
| Sacituzumab govitecan | Gilead Sciences | Phase 1/2 | 40 |
| regorafenib + nivolumab + FOLFOX chemotherapy with oxaliplatin | Bristol Myers Squibb | Phase 2 | 51 |
| 18F-BMS-986229 Injection + IV 18F-BMS-986229 | Bristol Myers Squibb | Pre-clinical | 22 |